Evidence map›Paper›PMID 41709466›Full record

ArticleCell genomics2026

Comparative genomics reveals LINE-1 recombination with diverse RNAs.

Cheuk-Ting Law, Kathleen H Burns

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Cheuk-Ting LawDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Pathology, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: cheuk-ting_law@dfci.harvard.edu.
Kathleen H BurnsDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Pathology, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: kathleenh_burns@dfci.harvard.edu.

Funding

Revealing Cellular Determinants of LINE-1 Retrotransposition OutcomesK99GM157510 · NIGMS · DANA-FARBER CANCER INST · PI Cheuk-Ting Law · 2025 to 2026
$234k
NIGMS NIH HHS K99 GM157510
6 · The paper itself

Abstract

Long interspersed element-1 (LINE-1, L1) retrotransposons are the most abundant protein-coding transposable elements (TEs) in mammalian genomes and have shaped genome content over 170 million years of evolution. LINE-1 is self-propagating and mobilizes other sequences, including Alu elements. Occasionally, LINE-1 forms chimeric insertions with non-coding RNAs and mRNAs, but there are no comprehensive catalogs of LINE-1 chimeras. To address this, we developed timing mobile element insertions (TiMEstamp), a computational pipeline that leverages multiple sequence alignments (MSAs) to estimate the age of LINE-1 insertions and identify candidate chimeric insertions where an adjacent sequence arrives contemporaneously. With this pipeline, we discovered new chimeric insertions involving small RNAs, Alu elements, and mRNA fragments. Additionally, we saw evidence that LINE-1 loci with defunct promoters can acquire regulatory elements from nearby genes to restore expression and retrotransposition activity. These discoveries highlight the recombinatory potential of LINE-1 RNA with implications for genome evolution, TE domestication, and somatic retrotransposition.

Indexed as

GenomicsLong Interspersed Nucleotide ElementsRecombination, GeneticRNAAlu ElementsAnimalsEvolution, MolecularHumansRNA, MessengerRNARNA, Messenger5′ transductionAluchimeric insertionscomparative genomicsLINE-1multiple sequence alignmentreverse transcriptionsplicingtransposable elementsU6 snRNA

Identifiers

PMID41709466
PMCPMC13174262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.